Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 12:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 577 matching trials from the live ClinicalTrials.gov search.
Conditions
Joint Prosthesis
Interventions
68-Gallium citrate PET/CT scan, 18F FDG PET/CT scan
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Newark, New Jersey
Conditions
Pancreatic Cancer, Breast Cancer, Hepatocellular Carcinoma
Interventions
Piflufolastat F18
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cancer, Solid Malignant Tumors, SCC - Squamous Cell Carcinoma, HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity
Interventions
Intra-op PET/CT Specimen Scanner
Device
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Cancer Diagnosis, Diagnostic Techniques and Procedures, Diagnostic Imaging
Interventions
F-18 FDG, Ga-68-DOTA-TATE, Positron Emission Tomography / Computed Tomography (PET/CT) Scan, Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Completed Not applicable Interventional Results available

PET/CT-Assessment of Liver Tumor Ablation

NCT02018107
Conditions
Liver Tumor, Liver Neoplasms
Interventions
N-13 ammonia or F-18 fluorodeoxyglucose, PET scan
Diagnostic Test
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Diagnostic Imaging, Neoplasms
Interventions
BAY94-9392
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
35 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Stanford, California
Completed Phase 3 Interventional Results available

Study of Diagnostic Performance of [18F]CTT1057 in BCR

NCT04838613
Conditions
Prostatic Neoplasms, Prostate Cancer, Recurrence
Interventions
[18F]CTT1057, [68Ga]Ga-PSMA-11
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Completed Not applicable Interventional Accepts healthy volunteers Results available

EXPLORER PET/CT: Evaluation of Healthy Individuals From Racial/Ethnic Minority Populations

NCT04812080
Conditions
Healthy Volunteers From Racial/Ethnic Minority Populations
Interventions
EXPLORER PET/CT
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Sacramento, California
Conditions
Brain Tumors and/or Solid Tumors Including, Brain Stem Glioma, High Grade CNS Tumors, Ependymoma, Medulloblastoma, Craniopharyngioma, Low Grade CNS Tumors, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma, Other
Interventions
Methionine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET/CT

NCT04062526
Conditions
Parkinson Disease, Healthy Volunteer
Interventions
[18F]NOS
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Late Onset Alzheimer Disease
Interventions
BAY 94-9172 (Florbetaben)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
65 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma
Interventions
18F-fluciclovine, PET/CT
Drug · Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Glioblastoma, Glioma
Interventions
Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
124 PET/CT imaging, Na134I, Tri-iodothyronine
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Stanford, California
Conditions
AL Amyloidosis
Interventions
124I-labeled monoclonal antibody Mu 11-1F4
Biological
Lead sponsor
University of Tennessee
Other
Eligibility
21 Years to 90 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Neoplasms
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Stanford, California
Conditions
Cardiac Sarcoidosis, Myocardial Inflammation
Interventions
18F-FSPG
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Stanford, California
Conditions
Focus of Study is Imaging Performance With the New Technology Compared With the Currently Available Technology.
Interventions
Additional PET Scan
Device
Lead sponsor
Philips Healthcare
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Uterine Cervical Neoplasms, Endometrial Neoplasms, Anus Neoplasms, Rectal Neoplasms, Prostatic Neoplasms
Interventions
fluorothymidine F 18
Drug
Lead sponsor
John M. Buatti
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma in Cervical Lymph Node
Interventions
Computed Tomography, Fluciclovine F18, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cancer
Interventions
[18F]fluoro-2-deoxy-D-glucose (FDG)
Drug
Lead sponsor
University of Utah
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Breast Cancer, Metastatic Invasive Lobular Breast Cancer
Interventions
18F-FAPI-74, 18F-FDG, PET/CT
Drug · Procedure
Lead sponsor
Randy Yeh
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Cancer AJCC v7
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
No Longer Available No phase listed Expanded access

89Zr-DFO-girentuximab Expanded Access Program (EAP)

NCT06090331
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
89Zr-DFO-girentuximab
Diagnostic Test
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Industry
Eligibility
18 Years to 99 Years
U.S. locations
22
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 19 more